Вход на сайт Запомнить (не выбирайте, если чужой компьютер) Забыли Пароль? Пожалуйста, заполните корректно обязательные поля. Регистрация Зарегистрируйтесь, чтобы пользоваться всеми независимыми медицинскими ресурсами и новостями на Univadis®
Новости медицины ECDC threat assessment brief on possible reinfection with SARS-CoV-2 Univadis Medical News 22.09.2020 So far, possible cases of re-infection have been reported in six countries, with other suspected cases under investigation. European Medicines Agency approves first treatment for alkaptonuria Univadis Medical News 22.09.2020 The EMA opinion will now be sent to the European Commission for the adoption of a decision on an EU-wide marketing authorisation. New oral treatment for moderate to severe atopic dermatitis Univadis Medical News 22.09.2020 Baricitinib is the first JAK inhibitor to treat moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy. Посмотреть все >
Новости медицины ECDC threat assessment brief on possible reinfection with SARS-CoV-2 Univadis Medical News 22.09.2020 So far, possible cases of re-infection have been reported in six countries, with other suspected cases under investigation. European Medicines Agency approves first treatment for alkaptonuria Univadis Medical News 22.09.2020 The EMA opinion will now be sent to the European Commission for the adoption of a decision on an EU-wide marketing authorisation. New oral treatment for moderate to severe atopic dermatitis Univadis Medical News 22.09.2020 Baricitinib is the first JAK inhibitor to treat moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy. Посмотреть все >
Популярное Вакцинация Все основные вопросы Вакцинация на одном ресурсе Онкология Все основные вопросы онкологии на одном ресурсе
Univadis
